Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05723653 · ClinicalTrials.gov registry record · NA
Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention
A NA study of HIV Seropositivity, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 900
- Enrollment target
- 7
- Study locations
NCT05723653: Recruiting NA study of HIV Seropositivity, sponsored by University of Chicago.
NCT05723653 is a NA study of HIV Seropositivity that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 900 participants, above the 184-participant average among 4 other HIV Seropositivity trials with a reported enrollment target (389% higher). The trial reports 7 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05723653, a NA study of HIV Seropositivity, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 900 participants
- Enrollment target
- 7
- Study locations
Study Summary
The goal of this Hybrid Type I effectiveness-implementation trial is to test an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among people living with HIV aged 18-49.
Primary Outcome
We count visits as scheduled (non-acute) visits to an antiretroviral prescribing provider. Missed Visit Proportion (MVP) is calculated as the proportion of total scheduled visits that are missed during the follow-up period. To permit longitudinal analyses, we shall also split the two-year follow-up period into eight three-month quarters and record, for each participant, whether he completed or missed his scheduled appointment during that quarter. Appointment and visit history to calculate MVP wi
Conditions Studied
Interventions
- BEHAVIORAL Social Network Support Intervention
Study Locations (7)
Alabama
- University of Alabama at Birmingham 1917 Clinic - Birmingham
- Birmingham AIDS Outreach - Birmingham
- Thrive Alabama - Huntsville
Illinois
- Howard Brown Health - Chicago
- Chicago Center for HIV Elimination - Chicago
- Crown Family School of Social Work, Policy, and Practice at the University of Chicago - Chicago
Louisiana
- Tulane University - New Orleans
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2023-02-13 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT05723653 shows while recruiting
NCT05723653 is an interventional study that assigns participants to a tested intervention. The registered 900 participants enrollment target is mid-sized for trials with a published cap, above the 184-participant average among 4 other HIV Seropositivity trials with a reported enrollment target (389% higher).
The record links to 1 condition, with HIV Seropositivity appearing as the primary indexed condition, and to 1 intervention - of which Social Network Support Intervention is the first listed.
NCT05723653 lists 7 locations in 3 states (Alabama, Illinois, Louisiana).
Frequently Asked Questions
What is clinical trial NCT05723653 about?
NCT05723653 is a clinical study titled "Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention". The goal of this Hybrid Type I effectiveness-implementation trial is to test an evidence-based, flexible, and tailored intervention that leverages existing social network members to promote retention in care and viral suppression among people living with HIV aged 18-49.
What is the current status of trial NCT05723653?
This trial is currently recruiting. It is a NA study. The enrollment target is 900 participants. The study started on 2023-02-13. Estimated completion is 2027-12-31.
What conditions does trial NCT05723653 study?
This clinical trial studies the following conditions: HIV Seropositivity.
What interventions are being tested in trial NCT05723653?
The interventions under investigation include: Social Network Support Intervention (BEHAVIORAL).
Who is sponsoring clinical trial NCT05723653?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05723653 being conducted?
This trial has 7 study locations across Alabama, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Seropositivity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
ACTIVE NOT RECRUITING · NA
-
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
COMPLETED · Phase 2
-
Safer Conception Intervention for HIV-1 Serodiscordant Couples
COMPLETED
-
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02352116 · 900 participants · NA
Evaluation of Post-PACU Pain Management in Pediatric Surgery
- NCT02414347 · 900 participants
F 18 T807 Tau PET Imaging of Alzheimer's Disease
- NCT02670408 · 900 participants
Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation
- NCT02960022 · 900 participants · Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI